Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 2 years and older and for other types of seizures in patients of all ages.
### Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Adjunctive treatment of other seizure types in patients 2 years of age and older.
### Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily. Titrate dose slowly by 5-10 mg every week to a maximum of 20 mg twice daily.
* **Other Seizures:** Initial dose: 5 mg twice daily. Titrate dose slowly by 5-10 mg every week to a maximum of 20 mg twice daily. Some patients may require higher doses, up to 30 mg twice daily, under strict medical supervision.
### Pediatric Dosing (2 years and older)
* **LGS:** Initial dose: 5 mg twice daily. Titrate dose slowly by 5-10 mg every week to a maximum of 20 mg twice daily.
* **Other Seizures:** Initial dose: 5 mg twice daily. Titrate dose slowly by 5-10 mg every week to a maximum of 20 mg twice daily.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited; consider a lower starting dose and slow titration.
* **Renal Impairment:** No specific dose adjustment is recommended, but use with caution.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea syndrome.
### Adverse Effects
Common adverse effects include somnolence, decreased appetite, aggression, irritability, constipation, gait disturbance, and vomiting. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, and respiratory depression.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inducers/Inhibitors:** Clobazam is a substrate of CYP3A4. Inducers may decrease clobazam levels, while inhibitors may increase them.
* **Other Anticonvulsants:** Clobazam may affect the metabolism of other anticonvulsants, and vice versa. Monitor for efficacy and toxicity.
### Monitoring
* Monitor for signs of somnolence and withdrawal symptoms.
* Monitor for suicidal behavior or ideation.
* Monitor for severe skin reactions.
* Monitor for respiratory depression, especially when used with other CNS depressants.
* Monitor for efficacy and adverse effects.
### Clinical Pearls
* Clobazam can be taken with or without food.
* Due to the risk of withdrawal symptoms, abrupt discontinuation should be avoided. Taper the dose gradually if discontinuing.
* The active metabolite, N-desmethylclobazam, has a long half-life, contributing to its sustained effect.
* Clobazam is associated with a risk of serious skin reactions, including SJS/TEN. Patients should be educated to discontinue the drug and seek immediate medical attention if a rash develops.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines before making any treatment decisions.
